Frontiers in Oncology (May 2024)
Impact of treatment and clinical characteristics on the survival of children with medulloblastoma in Mexico
- Violeta Salceda-Rivera,
- Isidoro Tejocote-Romero,
- Isidoro Tejocote-Romero,
- Diana S. Osorio,
- Rosalba Bellido-Magaña,
- Araceli López-Facundo,
- Susana E. Anaya-Aguirre,
- Daniel Ortiz-Morales,
- Daniel Ortiz-Morales,
- Roberto Rivera-Luna,
- Evelyne Reyes-Gutiérrez,
- Rebeca Rivera-Gómez,
- Liliana Velasco-Hidalgo,
- Deyanira Cortés-Alva,
- Sandra Lagarda-Arrechea,
- Farina E. Arreguín-González,
- Alma E. Benito-Reséndiz,
- Silvia Chávez-Gallegos,
- Eloy Pérez-Rivera,
- Guillermo J. Gaytán-Fernández,
- Guillermo J. Gaytán-Fernández,
- José A. León-Espitia,
- Jociela Domínguez-Sánchez,
- Carlos Leal-Cavazos,
- Citlalli Simón-González,
- Tania C. Larios-Farak,
- Nubia A. Macías-García,
- Ana C. García-Espinosa,
- Francisco Guerrero-Maymes,
- Paola Casillas-Toral,
- Oscar González-Ramella
Affiliations
- Violeta Salceda-Rivera
- Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”, Department of Pediatrics, Divisions of Pediatric Hematology-Oncology, Guadalajara, Jalisco, Mexico
- Isidoro Tejocote-Romero
- IMIEM, Instituto Materno Infantil del Estado de Mexico, Secretaria de Salud, Toluca, Estado de Mexico, Mexico
- Isidoro Tejocote-Romero
- Department of Pediatric Oncology, ISSEMYM, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Estado de Mexico, Mexico
- Diana S. Osorio
- ICON PLC, Clinical Research Organization, Dublin, Ireland
- Rosalba Bellido-Magaña
- Hospital General Regional de Leon, Leon, Guanajuato, Mexico
- Araceli López-Facundo
- Department of Pediatric Oncology, ISSEMYM, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Estado de Mexico, Mexico
- Susana E. Anaya-Aguirre
- Instituto Mexicano del Seguro Social, Centro Médico Nacional La Raza, Mexico City, Mexico
- Daniel Ortiz-Morales
- Department of Pediatric Oncology, Hospital General de México “Dr. Eduardo Liceaga”, Mexico City, Mexico
- Daniel Ortiz-Morales
- Department of Pediatric Oncology, Hospital Militar de Especialidades de la Mujer y Neonatología, Mexico City, Mexico
- Roberto Rivera-Luna
- Department of Pediatric Oncology, Instituto Nacional de Pediatria, Mexico City, Mexico
- Evelyne Reyes-Gutiérrez
- 0Hospital de Especialidades del Niño y de la Mujer, Secretaria de Salud, Queretaro, Mexico
- Rebeca Rivera-Gómez
- 1Hospital General de Tijuana, Universidad Autonoma de Baja California, Tijuana, Baja California, Mexico
- Liliana Velasco-Hidalgo
- Department of Pediatric Oncology, Instituto Nacional de Pediatria, Mexico City, Mexico
- Deyanira Cortés-Alva
- 2Hospital del Niño DIF Hidalgo, Sistema Nacional para el Desarrollo Integral de la Familia, Hidalgo, Mexico
- Sandra Lagarda-Arrechea
- 3Department of Pediatric Oncology, Instituto Estatal de Cancerologia, Colima, Mexico
- Farina E. Arreguín-González
- 4Centro Médico Nacional “20 de Noviembre” del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico
- Alma E. Benito-Reséndiz
- 4Centro Médico Nacional “20 de Noviembre” del Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (ISSSTE), Mexico City, Mexico
- Silvia Chávez-Gallegos
- 5Department of Pediatric Oncology, Hospital Infantil “Eva Samano de López Mateos”, Morelia, Michoacan, Mexico
- Eloy Pérez-Rivera
- 5Department of Pediatric Oncology, Hospital Infantil “Eva Samano de López Mateos”, Morelia, Michoacan, Mexico
- Guillermo J. Gaytán-Fernández
- Hospital General Regional de Leon, Leon, Guanajuato, Mexico
- Guillermo J. Gaytán-Fernández
- 6Department of Pediatric Oncology, Hospital Regional de Alta Especialidad del Bajío, Leon, Guanajuato, Mexico
- José A. León-Espitia
- Hospital General Regional de Leon, Leon, Guanajuato, Mexico
- Jociela Domínguez-Sánchez
- 7Department of Pediatric Oncology, Centenario Hospital Miguel Hidalgo, Aguascalientes, Mexico
- Carlos Leal-Cavazos
- 8Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo Leon, Nuevo Leon, Mexico
- Citlalli Simón-González
- 9Department of Pediatric Oncology, Hospital Regional de Alta Especialidad del Niño “ Dr. Rodolfo Nieto Padrón”, Tabasco, Mexico
- Tania C. Larios-Farak
- 0Department of Pediatric Oncology, Hospital Infantil del Estado de Sonora, Hermosillo, Sonora, Mexico
- Nubia A. Macías-García
- 1Department of Pediatric Oncology, Hospital del Niño “Dr. Federico Gómez Santos”, Saltillo, Coahuila, Mexico
- Ana C. García-Espinosa
- 2Department of Pediatric Oncology, Hospital Infantil de Especialidades de Chihuahua, Chihuahua, Chihuahua, Mexico
- Francisco Guerrero-Maymes
- 3Department of Pediatric Oncology, Hospital General de Occidente, Zapopan, Jalisco, Mexico
- Paola Casillas-Toral
- Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”, Department of Pediatrics, Divisions of Pediatric Hematology-Oncology, Guadalajara, Jalisco, Mexico
- Oscar González-Ramella
- Hospital Civil de Guadalajara “Dr. Juan I. Menchaca”, Department of Pediatrics, Divisions of Pediatric Hematology-Oncology, Guadalajara, Jalisco, Mexico
- DOI
- https://doi.org/10.3389/fonc.2024.1376574
- Journal volume & issue
-
Vol. 14
Abstract
IntroductionData on medulloblastoma outcomes and experiences in low- and middle-income countries, especially in Latin America, is limited. This study examines challenges in Mexico’s healthcare system, focusing on assessing outcomes for children with medulloblastoma in a tertiary care setting.MethodsA retrospective analysis was conducted, involving 284 patients treated at 21 pediatric oncology centers in Mexico.ResultsHigh-risk patients exhibited markedly lower event-free survival than standard-risk patients (43.5% vs. 78.3%, p<0.001). Influential factors on survival included anaplastic subtype (HR 2.4, p=0.003), metastatic disease (HR 1.9, p=0.001); residual tumor >1.5cm², and lower radiotherapy doses significantly impacted event-free survival (EFS) and overall survival (OS). Platinum-based chemotherapy showed better results compared to the ICE protocol in terms of OS and EFS, which was associated with higher toxicity. Patients under 3 years old displayed notably lower OS and EFS compared to older children (36.1% vs. 55.9%, p=0.01).
Keywords
- medulloblastoma
- survival
- clinical characteristics
- low and middle income countries
- CNS tumors
- childhood